Product Description
Mechanisms of Action: Akt Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Merck
Company Location: KENILWORTH NJ 07033
Company CEO: Robert M. Davis
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Brazil, Italy, United Kingdom, United States
Active Clinical Trial Count: 4
Highest Development Phases
Phase 2: Other|Proteus Infections|Proteus Syndrome
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| MK-7075-006 | P2 |
Active, not recruiting |
Proteus Syndrome|Proteus Infections |
2026-09-29 |
|
| MK-7075-006 | P2 |
Unknown Status |
Proteus Syndrome |
2025-12-15 |
|
| Miransertib Extension Study for PROS / PS Patients | P2 |
Active, not recruiting |
Proteus Syndrome |
2025-09-15 |
|
| ARQ 092-103 | P2 |
Active, not recruiting |
Other |
2019-07-14 |